Aligos Therapeutics, a Phase 1 biotech developing oligonucleotide therapies for viral and liver diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The company's lead focus is to develop a functional cure for Chronic Hepatitis B (CHB). The company has developed a portfolio of differentiated drug candidates for CHB, including ALG-010133, an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule. ALG-010133 is currently in a Phase 1 proof of concept trial in New Zealand.
The South San Francisco, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol ALGS. Aligos Therapeutics filed confidentially on August 26, 2020. J.P. Morgan, Jefferies, Piper Sandler and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
